Ruth Hager

Ruth Hager is Director, Pharmacovigilance at Priovant Therapeutics. Ruth holds a Bachelor of Science degree in Nursing from Northeastern University and worked in critical care and research before starting her career in the pharmaceutical industry. She has previously worked for pharma companies within multiple therapeutic areas, as well as a large CRO. Her expertise includes management of all aspects of pharmacovigilance from clinical drug development (phase I through IV) to the management of marketed compounds, aggregate report management, safety surveillance, safety database governance, regulatory compliance, vendor management, and audits.